HUTCHMED (China) (NASDAQ:HCM) Bolsa

HUTCHMED (China)

HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

Somnigroup International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGI#NYSE">SGI</a>) has outperformed the market over the past 15 years by 3.36% on an annualized basis producing an average annual return of 15.78%. Currently, Somnigroup International has a market capitalization of $14.99 billion. 
Buying $1000 In SGI: If an investor had bought $1000 of SGI stock 15 years ago, it would be worth $8,939.05 today based on a price of $71.87 for SGI at the time of writing.
<h3>Somnigroup International's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751670914_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In Somnigroup International 15 Years Ago Would Be Worth This Much Today

More than a decade ago, Warren Buffett said the national deficit could be <a href="https://www.benzinga.com/personal-finance/25/02/43904075/warren-buffett-said-he-could-end-u-s-deficit-in-5-minutes-if-you-guys-cant-get-it-done-well-get-some-other-guys-to-get-it-done">solved in just five minutes</a>. His plan? "You just pass a law that says that any time there is a deficit of more than 3% of GDP, all sitting members of Congress are ineligible for reelection."
That 2011 quote, from an interview with <a href="https://www.cnbc.com/2011/07/07/warren-buffetts-5minute-plan-to-fix-the-deficit.html">CNBC's Becky Quick</a>, resurfaced in early June — and this time, it gained traction with one of the world's most influential voices.
On June 4, Utah Sen. Mike Lee (R-UT) <a href="https://x.com/BasedMikeLee/status/1930222931377844568">posted the clip on X</a> and asked, "Would you support this amendment?" Elon Musk didn't hesitate. He <a href="https://x.com/elonmusk/status/1930298268661232083">reposted it</a> with the words "100%" and "This is the way," signaling full endorsement of Buffett's blunt solution.
Don't Miss:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. </a></li>
<li>Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a></li>
</ul>
The idea, while simple on its face, taps into longstanding frustration over congressional accountability and ballooning debt. Buffett originally framed the plan as a tongue-in-cheek solution to Washington gridlock, but made it clear he believed politicians would act faster if their jobs were on the line.
"I can end the deficit in five minutes," he told Quick at the time. "It's just that simple."
Back in 2011, the U.S. <a href="https://www.cbo.gov/publication/42532">deficit hovered just over $1 trillion</a>, about 8.5% of GDP. Today, it's projected to top $1.9 trillion — or roughly 6.7% of GDP. By Buffett's rule, Congress would have long since cleared out.
Lee, who reposted the clip on X, seemed to agree — and has hinted at wanting to turn it into real policy. In fact, several of his <a href="https://x.com/basedmikelee/status/1930454376000217304">recent posts call for stricter balanced budget</a> measures and constitutional amendments to force fiscal discipline. But translating Buffett's viral soundbite into actual legislation would require a two-thirds majority in both chambers or a convention of states — a high bar in any political climate.
Trending: Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a>
Musk's endorsement of the idea adds fuel, though. His ability to move public opinion — and occasionally policy discussion — with a single post has made him one of the most unpredictable influencers in politics, even without holding office.
The Buffett clip is gaining renewed momentum among fiscal hawks and frustrated taxpayers alike. And while Buffett may have said it half in jest, the message still lands with a punch: if lawmakers were held personally accountable for the budget, the deficit might not be a recurring headline.
Buffett and Musk <a href="https://www.benzinga.com/news/25/03/44075038/warren-buffett-says-he-has-spoken-to-elon-musk-a-few-times-but-repeatedly-dodges-questions-about-tesla-ceos-doge-efforts-well-i-better-not-get-into-all-that">haven't always been aligned</a>. Buffett famously declined to invest in Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), favoring Chinese automaker BYD instead. Musk, in turn, has publicly taken jabs at Buffett. "To be totally frank, I'm not his biggest fan," Musk told Joe Rogan on "<a href="https://youtu.be/RcYjXbSJBN8?si=AHItbBcTYYxDeQ-F">The Joe Rogan Experience</a>" in 2020. "He does a lot of capital allocation… reads a lot of annual reports… it's pretty boring, really."
But on this, they agree. Both men see congressional accountability as key to fixing the deficit—and Musk's viral repost gave Buffett's decade-old solution a jolt of relevance in today's debate.&nbsp;
Read Next:
<ul class="wp-block-list">
<li>Tired of Grid Failures and Charging Deserts? This Startup Has a Solar Fix and $25M+ in Sales — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Now Raising at $3/Share</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
Image: Shutterstock

Personal Finance

TSLA

Elon Musk Backs Warren Buffett's Brutal '5-Minute Deficit Fix' To Ban Congress From Reelection If They Blow the Budget: '100% This Is the Way'

Gartner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) has outperformed the market over the past 15 years by 8.14% on an annualized basis producing an average annual return of 20.56%. Currently, Gartner has a market capitalization of $30.81 billion. 
Buying $100 In IT: If an investor had bought $100 of IT stock 15 years ago, it would be worth $1,622.54 today based on a price of $400.28 for IT at the time of writing.
<h3>Gartner's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751670013_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Gartner 15 Years Ago Would Be Worth This Much Today

AMETEK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>) has outperformed the market over the past 20 years by 5.95% on an annualized basis producing an average annual return of 14.45%. Currently, AMETEK has a market capitalization of $42.50 billion. 
Buying $1000 In AME: If an investor had bought $1000 of AME stock 20 years ago, it would be worth $14,702.96 today based on a price of $184.19 for AME at the time of writing.
<h3>AMETEK's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751668212_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

American Financial Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFG#NYSE">AFG</a>) has outperformed the market over the past 5 years by 2.29% on an annualized basis producing an average annual return of 17.07%. Currently, American Financial Group has a market capitalization of $10.64 billion. 
Buying $100 In AFG: If an investor had bought $100 of AFG stock 5 years ago, it would be worth $208.70 today based on a price of $127.43 for AFG at the time of writing.
<h3>American Financial Group's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751667312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning American Financial Group Stock In The Last 5 Years

Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) has outperformed the market over the past 10 years by 20.06% on an annualized basis producing an average annual return of 31.86%. Currently, Monolithic Power Systems has a market capitalization of $37.01 billion. 
Buying $1000 In MPWR: If an investor had bought $1000 of MPWR stock 10 years ago, it would be worth $15,410.12 today based on a price of $758.66 for MPWR at the time of writing.
<h3>Monolithic Power Systems's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751666424_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MPWR

Here's How Much You Would Have Made Owning Monolithic Power Systems Stock In The Last 10 Years

In the current session, the stock is trading at $175.01, after a 1.48% spike. Over the past month, Fiserv Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) stock increased by 5.30%, and in the past year, by 16.27%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1751666417_0.png" alt="Past Year Chart" />

<h3>Fiserv P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 35.47 in the Financial Services industry, Fiserv Inc. has a lower P/E ratio of 30.52. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1751666417_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: Fiserv

Cenovus Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVE#NYSE">CVE</a>) has outperformed the market over the past 5 years by 11.09% on an annualized basis producing an average annual return of 25.88%. Currently, Cenovus Energy has a market capitalization of $25.40 billion. 
Buying $100 In CVE: If an investor had bought $100 of CVE stock 5 years ago, it would be worth $303.21 today based on a price of $14.00 for CVE at the time of writing.
<h3>Cenovus Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751665511_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Cenovus Energy 5 Years Ago Would Be Worth Today

Moodys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) has outperformed the market over the past 10 years by 4.83% on an annualized basis producing an average annual return of 16.64%. Currently, Moodys has a market capitalization of $90.88 billion. 
Buying $1000 In MCO: If an investor had bought $1000 of MCO stock 10 years ago, it would be worth $4,673.45 today based on a price of $505.06 for MCO at the time of writing.
<h3>Moodys's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751663728_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

GFL Environmental (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) has outperformed the market over the past 5 years by 5.63% on an annualized basis producing an average annual return of 20.42%. Currently, GFL Environmental has a market capitalization of $17.71 billion. 
Buying $100 In GFL: If an investor had bought $100 of GFL stock 5 years ago, it would be worth $255.75 today based on a price of $48.29 for GFL at the time of writing.
<h3>GFL Environmental's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751662815_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

In the current market session, Sherwin-Williams Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) share price is at $354.00, after a 0.42% spike. Moreover, over the past month, the stock decreased by 0.97%, but in the past year, increased by 17.90%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1751662815_0_0.png" alt="Past Year Chart" />

<h3>Sherwin-Williams P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 169.21 in the Chemicals industry, Sherwin-Williams Inc. has a lower P/E ratio of 33.32. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1751662815_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

P/E Ratio Insights for Sherwin-Williams

Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) has outperformed the market over the past 5 years by 6.43% on an annualized basis producing an average annual return of 21.21%. Currently, Carvana has a market capitalization of $46.99 billion. 
Buying $100 In CVNA: If an investor had bought $100 of CVNA stock 5 years ago, it would be worth $259.10 today based on a price of $348.00 for CVNA at the time of writing.
<h3>Carvana's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751661917_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVNA

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Liberty Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWONK#NASDAQ">FWONK</a>) has outperformed the market over the past 10 years by 3.34% on an annualized basis producing an average annual return of 15.15%. Currently, Liberty Media has a market capitalization of $25.69 billion. 
Buying $1000 In FWONK: If an investor had bought $1000 of FWONK stock 10 years ago, it would be worth $4,110.90 today based on a price of $103.00 for FWONK at the time of writing.
<h3>Liberty Media's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751661012_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FWONK

$1000 Invested In Liberty Media 10 Years Ago Would Be Worth This Much Today

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 60.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed up 22.01% at $0.25</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed up 14.50% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 14.27% at $1.04</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed up 10.20% at $0.54</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 8.70% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Growth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed up 8.38% at $1.28</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 7.10% at $0.29</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 3.86% at $0.31</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 3.58% at $0.05</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 25.00% at $0.0009</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 13.04% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 10.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed down 8.29% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 7.12% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Properties</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed down 6.40% at $0.54</li>
<li><a href="https://www.benzinga.com/quote/RIV">Rivernorth Opps Fund</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIV#NYSE">RIV</a>) shares closed down 4.46% at $12.35</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 4.23% at $0.86</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Movers

BBRRF

BLGVF

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CNBX

CNTMF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

FFNTF

ITHUF

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LVRLF

NWVCF

OILFF

TLRY

UGRO

YCBD

ZDPY

Bullish Sentiment Across The Cannabis Space - Check Full Movers For July 4, 2025

Performance Food Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFGC#NYSE">PFGC</a>) has outperformed the market over the past 5 years by 12.57% on an annualized basis producing an average annual return of 27.36%. Currently, Performance Food Gr has a market capitalization of $13.87 billion. 
Buying $1000 In PFGC: If an investor had bought $1000 of PFGC stock 5 years ago, it would be worth $3,291.48 today based on a price of $88.87 for PFGC at the time of writing.
<h3>Performance Food Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751660113_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PFGC

Here's How Much You Would Have Made Owning Performance Food Gr Stock In The Last 5 Years

A Reddit user claims they were offered what they call a dream job—a role created specifically for them, thanks to a rare skill set. But one small lie about their salary is now threatening the entire opportunity.
<h2 class="wp-block-heading">A $3K Lie And A Pay Stub Request</h2>
According to the <a href="https://www.reddit.com/r/careeradvice/comments/1lnfem1/a_potential_employer_offered_me_my_dream_job_but/">post</a> in Reddit&#8217;s r/careeradvice subreddit, the prospective employer offered $60,000 and asked for a recent pay stub to verify their current salary. The problem? The applicant told them they make $65,000. In reality, they earn $62,000.
Don't Miss:
<ul class="wp-block-list">
<li>Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a></li>
<li>Tired of Grid Failures and Charging Deserts? This Startup Has a Solar Fix and $25M+ in Sales — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Now Raising at $3/Share</a></li>
</ul>
The request for a pay stub struck many commenters as inappropriate, if not suspicious. &#8220;It's a red flag for them to even ask how much you currently make,&#8221; one person wrote. &#8220;I would say you're not comfortable providing a paystub, but they are welcome to verify your employment through a standard background check.&#8221;
Another user added, &#8220;That's wack, I&#8217;m glad it&#8217;s illegal where I live.&#8221;
<h2 class="wp-block-heading">&#8216;Dream Job&#8217; Or Red Flag?</h2>
While some were sympathetic to the applicant&#8217;s dilemma, many pointed out that the job offer didn't seem like much of a dream after all.
&#8220;I don&#8217;t know if you know what a <a href="https://www.benzinga.com/personal-finance/25/05/45565105/becoming-a-flight-attendant-was-supposed-to-be-a-dream-job-instead-it-wrecked-their-finances-its-been-financially-devastating">dream job</a> is, or maybe you have sh&#x2A;tty dreams but a salary decrease and you&#8217;re losing benefits, PTO, and a week off on Xmas? How is this a dream job?&#8221; one person asked. On the other hand, the original poster said their <a href="https://www.benzinga.com/25/05/45445458/i-got-a-new-job-with-my-dream-salary-but-now-i-miss-my-old-job-suze-orman-offers-some-advice">current job isn&#8217;t a good fit</a> for them and &#8220;isn&#8217;t going well.&#8221;
Still, others questioned the value of the so-called rare skill set. &#8220;People with very rare skills don&#8217;t command salaries in the mid-60s,&#8221; a commenter said.
Trending: Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a>
<h2 class="wp-block-heading">Should They Fake It?</h2>
The thread also sparked a fierce debate about ethics. Some people encouraged OP to forge a pay stub. &#8220;Sometimes in life you take the easiest path,&#8221; one user said. &#8220;Capitalism is a big f&#x2A;&#x2A;&#x2A;n game.&#8221;
But most strongly advised against it. &#8220;Falsifying a pay stub is illegal as it is considered fraud with intent to gain monetarily,&#8221; one commenter warned. &#8220;It's a recipe for getting fired when they find out.&#8221;
Instead, people suggested the person lean into the truth and negotiate based on total compensation, not just salary. They should explain that they won't share a stub, but that the $65,000 number reflects total compensation, including health insurance, PTO, and bonuses.
&#8220;This isn't some aha gotcha moment,&#8221; another person reassured. &#8220;$3,000 is a rounding error. Most people round when talking about salary.&#8221;
See Also: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation.&nbsp;</a>
<h2 class="wp-block-heading">A Lesson In Negotiation</h2>
Another popular comment summed it up like this: &#8220;Your salary requirements for the new job should be based on the actual role and responsibilities for this type of position, your overall job experience, AND what the average salary is in your industry for this role.&#8221;
If the company insists on a pay stub, most commenters agree it&#8217;s not worth it. They should say: &#8216;$65K is the salary I would need to take this job. Thank you for your consideration.&#8217; And that's the end of the discussion.&#8221;
Read Next: How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.
Image: Shutterstock

They Got A Rare Offer—A Role Created Just For Them. But One Lie About Pay Could Cost Them Everything. Should They Use 'Shady Methods?'

Cullen/Frost Bankers's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFR#NYSE">CFR</a>) short percent of float has fallen 15.78% since its last report. The company recently reported that it has 1.76 million shares sold short, which is 3.15% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Cullen/Frost Bankers Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751659233_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cullen/Frost Bankers has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Cullen/Frost Bankers's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Cullen/Frost Bankers's peer group average for short interest as a percentage of float is 4.33%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Cullen/Frost Bankers's Recent Short Interest

HCA Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) short percent of float has risen 3.98% since its last report. The company recently reported that it has 4.64 million shares sold short, which is 2.61% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.02 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>HCA Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751659228_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for HCA Healthcare has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing HCA Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, HCA Healthcare's peer group average for short interest as a percentage of float is 5.29%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Do Investors Really Feel About HCA Healthcare?

eBay's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NYSE">EBAY</a>) short percent of float has fallen 18.99% since its last report. The company recently reported that it has 23.65 million shares sold short, which is 5.93% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.37 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>eBay Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751659223_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for eBay has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing eBay's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, eBay's peer group average for short interest as a percentage of float is 10.96%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

EBAY

How Is The Market Feeling About eBay?

In the current market session, Golub Capital BDC Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBDC#NASDAQ">GBDC</a>) price is at $14.77, after a 0.68% spike. However, over the past month, the stock fell by 2.31%, and in the past year, by 7.28%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1751659215_0.png" alt="Past Year Chart" />

<h3>Comparing Golub Capital BDC P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Golub Capital BDC has a lower P/E than the aggregate P/E of 18.03 of the Capital Markets industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1751659215_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

GBDC

P/E Ratio Insights for Golub Capital BDC

Press Releases

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

General

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025

UPDATE - International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

Health Care

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

HUTCHMED to Announce 2025 Half-Year Financial Results

ABBNY

BDOUY

BLTE

BVNRY

CLCGY

EPOAY

FPAFY

ICAGY

IFNNY

VIOT

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

HUTCHMED (China)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL